Morcellator Lawsuit Alleges Gyrus Power Morcellator Promoted Growth of Abdominal Tumors, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) October 16, 2014
A new morcellator lawsuit (http://www.gynecaremorcellatorlawsuit.com/) has been filed on behalf of a California woman who claims that the use of a Gyrus Power Morcellator during a minimally-invasive hysterectomy promoted the growth of seven cancerous tumors in her abdomen. The complaint, which was filed on U.S. District Court for the Eastern District of California, further alleges that Gyrus ACMI LP failed to provide adequate warning about the morcellator's potential to spread undetected cancer cells present in the uterus throughout a patient's body. (Nielsen, et ux. v. Gyrus Acmi LLC, No. 2:14-2375)
"Our Firm has heard from a number of women who claim that their experiences with uterine morcellation were very similar to this plaintiff. We are monitoring the growing litigation involving power morcellators very closely," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating potential morcellator lawsuits on behalf of women who may have experienced the spread of undiagnosed uterine sarcoma and other cancers due to uterine morcellation.
Uterine Morcellation and Cancer Power morcellators are used in laparoscopic hysterectomies and fibroid removals to shred tissue so that it can be easily removed through a small incision in the abdomen. In April, the U.S. Food & Drug Administration (FDA) warned that use of the devices in gynecological procedures could spread undetected uterine cancer cells throughout a woman's body. The FDA stated that roughly 1 in 350 women with fibroids actually has undiagnosed uterine sarcoma, and that dissemination of those cancer cells outside of the uterus can greatly reduce a woman's chances for long-term survival.
In August, Highmark, Inc., one of the nation's largest Blue Cross/Blue Shield insurance companies said it would stop paying for the surgeries as of September 1st. * In Massachusetts, Blue Cross-Blue Shield of Massachusetts, Harvard Pilgrim and Fallon Health have also limited their coverage of uterine morcellation.** Johnson & Johnson has also pulled several power morcellators marketed by Ethicon, Inc. unit due to their uncertain safety profile.***
Women who allegedly experienced the spread of cancer due to uterine morcellation may be entitled to file a legal claim against the manufacturer of the device used in their surgery. To learn more about the process for filing a morcellator lawsuit, please visit Bernstein Liebhard LLPs website, or call the Firm directly for a free, no-obligation case review at 800-511-5092.
About Bernstein Liebhard LLP Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP 10 East 40th Street New York, New York 10016 800-511-5092